Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 229


Impact of the double expression of MYC and BCL2 on outcomes of localized primary gastric diffuse large B-cell lymphoma patients in the rituximab era.

Kawajiri A, Maruyama D, Maeshima AM, Nomoto J, Makita S, Kitahara H, Miyamoto KI, Fukuhara S, Suzuki T, Munakata W, Tajima K, Itami J, Taniguchi H, Kobayashi Y, Tobinai K.

Blood Cancer J. 2016 Sep 30;6(9):e477. doi: 10.1038/bcj.2016.88. No abstract available.


Prognostic role of pretreatment neutrophil-lymphocyte ratio in patients with diffuse large B-cell lymphoma treated with RCHOP.

Wang J, Zhou M, Xu JY, Yang YG, Zhang QG, Zhou RF, Chen B, Ouyang J.

Medicine (Baltimore). 2016 Sep;95(38):e4893. doi: 10.1097/MD.0000000000004893.


New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.

Cai QQ, Hu LY, Geng QR, Chen J, Lu ZH, Rao HL, Liu Q, Jiang WQ, Huang HQ, Lin TY, Xia ZJ.

Chin J Cancer. 2016 Sep 13;35(1):87. doi: 10.1186/s40880-016-0150-y.


Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update.

Hong JY, Suh C, Kim WS.

F1000Res. 2016 Aug 8;5. pii: F1000 Faculty Rev-1933. doi: 10.12688/f1000research.8790.1. Review.


Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies.

Frazzi R, Auffray C, Ferrari A, Filippini P, Rutella S, Cesario A.

J Transl Med. 2016 Sep 1;14:252. doi: 10.1186/s12967-016-1018-2. Review.


Radiotherapy for Non-Hodgkin's lymphoma: still standard practice and not an outdated treatment option.

Zimmermann M, Oehler C, Mey U, Ghadjar P, Zwahlen DR.

Radiat Oncol. 2016 Aug 30;11(1):110. doi: 10.1186/s13014-016-0690-y. Review.


The care center influences the management of lymphoma patients in a universal health care system: an observational cohort study.

Lamy S, Bettiol C, Grosclaude P, Compaci G, Albertus G, Récher C, Nogaro JC, Despas F, Laurent G, Delpierre C.

BMC Health Serv Res. 2016 Aug 2;16(a):336. doi: 10.1186/s12913-016-1553-9.


Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study.

Wu J, Song Y, Su L, Xu L, Chen T, Zhao Z, Zhang M, Li W, Hu Y, Zhang X, Gao Y, Niu Z, Feng R, Wang W, Peng J, Li X, Ouyang X, Wu C, Zhang W, Zeng Y, Xiao Z, Liang Y, Zhuang Y, Wang J, Sun Z, Bai H, Cui T, Feng J.

BMC Cancer. 2016 Jul 26;16:537. doi: 10.1186/s12885-016-2523-7.


Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.

Stephens DM, Li H, LeBlanc ML, Puvvada SD, Persky D, Friedberg JW, Smith SM.

J Clin Oncol. 2016 Sep 1;34(25):2997-3004. doi: 10.1200/JCO.2015.65.4582.


SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway.

Takagi Y, Shimada K, Shimada S, Sakamoto A, Naoe T, Nakamura S, Hayakawa F, Tomita A, Kiyoi H.

Cancer Sci. 2016 Sep;107(9):1270-80. doi: 10.1111/cas.13001.


Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma.

Tomono A, Ito K, Hayashi T, Ando M, Ando Y, Tsuge M, Okamoto A, Inaguma Y, Okamoto M, Emi N, Yamada S.

Cancer Chemother Pharmacol. 2016 Aug;78(2):305-12. doi: 10.1007/s00280-016-3076-9.


The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines.

Reinholdt L, Laursen MB, Schmitz A, Bødker JS, Jakobsen LH, Bøgsted M, Johnsen HE, Dybkær K.

Biomark Res. 2016 Jun 14;4:12. doi: 10.1186/s40364-016-0067-2.


Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.

de Oliveira Costa R, Hallack Neto A, Siqueira S, Lage LA, de Paula HM, Coutinho AM, Pereira J.

Nucl Med Commun. 2016 Oct;37(10):1095-101. doi: 10.1097/MNM.0000000000000553.


Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future.

Sorge CE, McDaniel JK, Xavier AC.

Pharmaceuticals (Basel). 2016 May 19;9(2). pii: E28. doi: 10.3390/ph9020028. Review.


Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results.

Stefoni V, Casadei B, Bottelli C, Gaidano G, Ciochetto C, Cabras MG, Ansuinelli M, Argnani L, Broccoli A, Gandolfi L, Pellegrini C, Zinzani PL.

Blood Cancer J. 2016 May 13;6:e425. doi: 10.1038/bcj.2016.29.


Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Go SI, Park MJ, Song HN, Kim HG, Kang MH, Lee HR, Kim Y, Kim RB, Lee SI, Lee GW.

J Cachexia Sarcopenia Muscle. 2016 Apr 12. doi: 10.1002/jcsm.12115.


Diffuse large B-cell lymphoma of the breast: prognostic factors and treatment outcomes.

Sun Y, Joks M, Xu LM, Chen XL, Qian D, You JQ, Yuan ZY.

Onco Targets Ther. 2016 Apr 6;9:2069-80. doi: 10.2147/OTT.S98566.


Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.

González-Barca E, Canales M, Salar A, Ferreiro-Martínez JJ, Ferrer-Bordes S, García-Marco JA, Sánchez-Blanco JJ, García-Frade J, Peñalver J, Bello-López JL, Sancho JM, Caballero D; GELTAMO group..

Ann Hematol. 2016 May;95(6):893-9. doi: 10.1007/s00277-016-2648-4.

Items per page

Supplemental Content

Support Center